TET2 and acute myeloid leukemia: Mutations in IDH1/2 lead to the neomorphic production of 2-hydroxyglutarate (2-HG), which inhibits TET2 activity, disrupts DNA demethylation, and contributes to epigenetic dysregulation in AML (Keum and Choi, 2015; Fujii et al., 2016; Gabellier et al., 2025).